Time-Restricted Feeding & Fasting

Navigation

Parent MOC: 01 - Foundations MOC | Literature Dossier: Time-Restricted Feeding & Fasting - References Related: Metabolic Flexibility & Insulin Sensitivity • Circadian Entrainment & Zeitgebers • Mitochondrial Energetics • Hydration & Electrolytes

---

1. Core Physiological Mechanisms

1. Circadian Alignment of Peripheral Oscillators (eTRE vs. Late TRE)

Insulin sensitivity, diet-induced thermogenesis (DIT), and pancreatic $\beta$-cell responsiveness follow a strong endogenous circadian rhythm that peaks in the morning and early afternoon and declines in the evening:

• Early Time-Restricted Eating (eTRE): Consolidating caloric intake into an 8–10 hour window earlier in the day (e.g., 08:00–16:00 or 09:00–18:00) synchronizes hepatic PER/CRY and REV-ERB$\alpha$ transcription with the SCN master clock.
• Evening Melatonin-Insulin Conflict: Eating within 2–3 hours of bedtime coincides with rising endogenous melatonin, which binds pancreatic $\beta$-cell ${\text{MT}}_2$ receptors and inhibits glucose-stimulated insulin secretion, resulting in prolonged nocturnal hyperglycemia and suppressed slow-wave sleep GH pulses.

2. The AMPK / SIRT1 / mTORC1 Nutrient-Sensing Switch

• Fed State (0–4 hours post-meal): Amino acids (specifically leucine and arginine via Sestrin2/CASTOR1) and insulin activate mTORC1, driving ribosomal biogenesis, muscle protein synthesis (MPS), and lipogenesis while phosphorylating/inhibiting ULK1 (blocking autophagy).
• Post-Absorptive & Fasted Transition (12–18 hours): Hepatic glycogen stores (~80–100 g) deplete; the falling $\text{ATP:AMP}$ and rising ${\text{NAD}}^{+}:\text{NADH}$ ratios activate AMPK and Sirtuin-1 (SIRT1). AMPK inhibits mTORC1 and directly phosphorylates ULK1 (Ser317/Ser777) and FOXO3a, initiating autophagosome formation and mitophagy.
• Deep Ketosis & Prolonged Fasting (24–72 hours): Adipose lipolysis releases free fatty acids that undergo hepatic $\beta$-oxidation into $\beta$-hydroxybutyrate (BHB, $1.5–4.0\text{mmol/L}$). BHB acts not only as a high-efficiency mitochondrial substrate ($\Delta G^{\prime }$ per oxygen atom superior to glucose) but also as a signaling metabolite:
  • Endogenous inhibitor of Class I Histone Deacetylases (HDACs), upregulating FOXO3a and MT2 antioxidant expression.
  • Direct inhibitor of the NLRP3 inflammasome, suppressing IL-1$\beta$ and IL-18 release.

---

2. Actionable Protocols & Fasting Architecture

Protocol	Feeding / Fasting Window	Target Population & Physiological Objective
Circadian 14:10 / 12:12 Baseline	10–12 h feeding (e.g., 08:00–18:00)	Sustainable baseline for high-volume athletes or individuals optimizing hypertrophy (allows 3–4 protein boluses) while preserving a 3–4 h pre-sleep fast
Early Time-Restricted Eating (eTRE 16:8)	8 h feeding (e.g., 08:00–16:00 or 09:00–17:00)	Optimal for reversing insulin resistance, lowering 24-hour glucose variability, reducing blood pressure, and upregulating nocturnal hepatic autophagy
Periodic 24–48h Prolonged Fast	24–48 h water + electrolytes (Quarterly / 2–4x per year)	Deep hepatic glycogen depletion, systemic BHB elevation ($>1.5\text{mmol/L}$), NLRP3 inflammasome suppression, and intestinal stem cell regeneration

Guardrails & Lean Mass Preservation

• Protein Density: Fasting windows must never compromise total daily protein targets ($1.6–2.2\text{g/kg/day}$; see Macronutrient & Micronutrient Optimization). Uncompensated caloric restriction during late-shifted 16:8 (skipping breakfast and under-consuming protein) risks lean appendicular skeletal muscle loss.
• Electrolyte Support: Insulin suppression during fasting triggers natriuresis of fasting (renal sodium and water excretion); supplement $3–5\text{g}$ sodium, $1\text{g}$ potassium, and $300–400\text{mg}$ magnesium during fasts $>18\text{ hours}$.

---

3. Summary of Key Scientific Evidence

• Isocaloric eTRE Improves Insulin Sensitivity Without Weight Loss: Sutton et al. (2018) demonstrated in a landmark 5-week randomized crossover controlled-feeding trial in Cell Metabolism that eTRE (6-hour feeding window ending before 15:00) significantly decreased fasting insulin by 3.4 mU/L, lowered postprandial insulin by 26 mU/L, reduced systolic/diastolic blood pressure by 11/10 mmHg, and lowered 8-isoprostane oxidative stress—completely independent of weight loss (Sutton et al., 2018).
• 10-Hour TRE in Metabolic Syndrome (TIMET RCT): Wilkinson et al. (2020) and Manoogian et al. (2024) (Annals of Internal Medicine, PMID: 39348690) demonstrated in RCTs of patients with metabolic syndrome that a 10-hour TRE window significantly improved ${\text{HbA}}_{1\text{c}}$, reduced visceral adiposity, and lowered atherogenic LDL particles alongside standard pharmacotherapy (Manoogian et al., 2024).
• Intermittent Fasting Systemic Review in NEJM: de Cabo & Mattson (2019) synthesized preclinical and human clinical evidence in the New England Journal of Medicine detailing how the fasting metabolic switch from hepatic glucose to ketone body ($\beta$-hydroxybutyrate) utilization activates adaptive cellular stress-response pathways (AMPK, SIRT1, PGC-1$\alpha$, autophagy, and DNA repair) (de Cabo & Mattson, 2019).
• $\beta$-Hydroxybutyrate Inhibits NLRP3 Inflammasome: Youm et al. (2015) demonstrated in Nature Medicine that the ketone body $\beta$-hydroxybutyrate (BHB)—but not acetoacetate or butyrate—directly blocks NLRP3 inflammasome assembly by preventing ${\text{K}}^{+}$ efflux and ASC oligomerization, reducing IL-1$\beta$ and IL-18 driven systemic inflammation (Youm et al., 2015).